Advertisement

Lights and shadows on JAK inhibitors for Ankylosing Spondylitis

      Ankylosing Spondylitis (AS) is an autoimmune disease characterized by inflammation of the spine and sacroiliac joints, historically described in young males with progressive structural damage of the spine, and later used as model to identify a group of inflammatory diseases known as Spondyloarthritis (SpA) [
      • Taurog J.D.
      • Chhabra A.
      • Colbert R.A.
      Ankylosing Spondylitis and Axial Spondyloarthritis.
      ]. AS is currently considered the advanced stage of Axial Spondyloarthritis (axSpA), when chronic joint inflammation has progressed to erosions and ankylosis, features that are detectable be means of conventional radiology (x-rays) and therefore defined as radiographic axial spondyloarthritis (r-axSpA)1 [
      • Sieper J.
      • Poddubnyy D.
      Axial spondyloarthritis.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Taurog J.D.
        • Chhabra A.
        • Colbert R.A.
        Ankylosing Spondylitis and Axial Spondyloarthritis.
        N Engl J Med. 2016; 374: 2563-2574
        • Sieper J.
        • Poddubnyy D.
        Axial spondyloarthritis.
        Lancet. 2017; 390: 73-84
        • Campochiaro C.
        • Caruso P.F.
        Ankylosing Spondylitis and Axial Spondyloarthritis.
        N Engl J Med. 2016; 375: 1302-1303
        • Navarro-Compán V.
        • Sepriano A.
        • El-Zorkany B.
        • van der Heijde D.
        Axial spondyloarthritis.
        Ann Rheum Dis. 2021; 80: 1511-1521
        • Baraliakos X.
        • Hermann K.G.A.
        • Braun J.
        Imaging in axial spondyloarthritis: diagnostic problems and pitfalls.
        Rheum Dis Clin North Am. 2012; 38: 513-522
      1. López-Medina C., Ramiro S., van der Heijde D., Sieper J., Dougados M., Molto A.. Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open. 2019;5(2).

        • Benavent D.
        • Navarro-Compán V.
        Understanding the paradigm of non-radiographic axial spondyloarthritis.
        Clin Rheumatol. 2021; 40: 501-512
        • Ward M.M.
        • Deodhar A.
        • Gensler L.S.
        • et al.
        2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
        Arthritis Rheumatol. 2019; 71: 1599-1613
        • van der Heijde D.
        • Ramiro S.
        • Landewé R.
        • et al.
        2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
        Ann Rheum Dis. 2017; 76: 978-991
        • Navarro-Compán V.
        • Plasencia-Rodríguez C.
        • de Miguel E.
        • Diaz-del-Campo P.
        • Balsa A.
        • Gratacós J.
        Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review.
        RMD Open. 2017; 3e000524
        • Campochiaro C.
        • Tomelleri A.
        • Galli E.
        • et al.
        Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?.
        Clin Exp Rheumatol. 2021; 39 Suppl 129: S129-S134
        • McLornan D.P.
        • Pope J.E.
        • Gotlib J.
        • Harrison C.N.
        Current and future status of JAK inhibitors.
        Lancet. 2021; 398: 803-816
        • Fragoulis G.E.
        • Mcinnes I.B.
        • Siebert S.
        JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
        Rheumatology (Oxford). 2019; 58 (Suppl): i43-i54
        • Akkoc N.
        • Khan M.A.
        JAK Inhibitors for Axial Spondyloarthritis: what does the Future Hold?.
        Curr Rheumatol Rep. 2021; 23
        • Parmentier J.M.
        • Voss J.
        • Graff C.
        • et al.
        In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).
        BMC Rheumatol. 2018; 2: 23
        • Traves P.G.
        • Murray B.
        • Campigotto F.
        • Galien R.
        • Meng A.
        • di Paolo J.A.
        JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
        Ann Rheum Dis. 2021; 80: 865-875
        • Ytterberg S.R.
        • Bhatt D.L.
        • Mikuls T.R.
        • et al.
        Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
        N Engl J Med. 2022; 386: 316-326
      2. Kragstrup T.W., Glintborg B., Svensson A.L., et al. Waiting for JAK inhibitor safety data. RMD Open. 2022;8(1).

        • Singh J.A.
        Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis — Past, Present, and Future.
        N Engl J Med. 2022; 386: 387-389
        • Li S.
        • Li F.
        • Mao N.
        • Wang J.
        • Xie X.
        Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis.
        Eur J Internal Med. 2022; 102: 45-51